摘要
结核分枝杆菌(mycobacterium tuberculosis,MTB)感染可表现为潜伏结核感染(latent tuberculosis infection,LTBI)和活动性结核病(active tuberculosis,ATB)。异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)是MTB感染的独立危险因素,allo-HSCT患者LTBI进展为ATB的风险高于一般人群[1-2]。由于机体免疫状态的改变,allo-HSCT患者合并ATB的临床表现和辅助检查可不典型,临床诊断困难。抗结核药物的毒性及其与预处理药物、免疫抑制剂等多种药物之间的相互作用,使allo-HSCT合并ATB的防治更为复杂与困难。
作者
中华医学会血液学分会
中华医学会结核病学分会
黄晓军
吴德沛
张晓辉
吴桂辉
庞宇
王昱
刘竞
张曦
姜尔烈
唐晓文
罗依
Chinese Society of Hematology,Chinese Medical Association;Chinese Society for Tuberculosis,Chinese Medical Association;Huang Xiaojun;Wu Depei;Zhang Xiaohui;Wu Guihui;Pang Yu(不详;Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China;The First Afiliated Hospital of Soochow University,Jiangsu Institute of Hematology,National Clinical Research Center for Hematologic Disease,Bejing Key Laboratory of Hematopoitic Stem Cell Transplantation,Suzhou 215006,China;Chengdu Public Healthh Clinical Medical Center,Chengdu 610016,China;Beijing Chest Hospital,Beijing Tuberculosis and Thoracic Tumor Research Institute,Capital Medical University,Beijing 101149,China)
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2023年第2期98-105,共8页
Chinese Journal of Hematology
